SCHEMBL1403417

SCHEMBL1403417

COC(=O)C=Cc1cccc(S(=O)(=O)Nc2ccc(F)cc2F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 11/20 0.53
▸ HDAC3 O15379 10/20 0.53
▸ HDAC1 Q13547 10/20 0.53
▸ HDAC7 Q8WUI4 10/20 0.53
▸ HDAC2 Q92769 10/20 0.53
▸ HDAC10 Q969S8 10/20 0.53
▸ HDAC11 Q96DB2 10/20 0.53
▸ HDAC8 Q9BY41 10/20 0.53
▸ HDAC6 Q9UBN7 10/20 0.53
▸ HDAC9 Q9UKV0 10/20 0.53
▸ HDAC5 Q9UQL6 10/20 0.53
▸ LMNA P02545 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ MPI P34949 1/20 0.50
▸ KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403416 1.00 HDAC4 (0.53) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403273 0.89 ALDH1A1 (0.63) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403274 0.89 ALDH1A1 (0.63) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403184 0.87 HDAC4 (0.56) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403182 0.87 HDAC4 (0.56) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1402707 0.86 HDAC4 (0.55) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1402705 0.86 HDAC4 (0.55) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403329 0.85 HDAC1 (0.72) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403330 0.85 HDAC1 (0.72) HDAC4HDAC3HDAC1HDAC7HDAC2
SCHEMBL1403159 0.85 HDAC1 (0.53) HDAC4HDAC3HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292593-A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2011-03-09 — — EP disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 — — US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 — — US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 — — US disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 — — US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 — — US disclosed
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors PROLIFIX LIMITED (GB) 2005-05-19 — — US disclosed
US-6888027-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2005-05-03 — — US disclosed
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPO TARGET UK LIMITED, (GB) 2005-04-21 — — US disclosed
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors SWK FUNDING LLC 2004-04-22 — — US disclosed
EP-1328510-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LTD. (GB) 2003-07-23 — — EP disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC3 3/4885HDAC1 1/4885
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC3 3/4885HDAC1 1/4885
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC3 3/4885HDAC1 1/4885
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors HDAC1, HDAC11, HDAC2 HDAC4 8/4885HDAC3 5/4885HDAC1 1/4885
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC4 8/4885HDAC3 3/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback